发明名称 FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR I
摘要 The present invention relates to compounds of formula I as defined herein. The compounds of the present invention are inhibitors of heat shock factor 1 (HSF1). In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.
申请公布号 US2017037036(A1) 申请公布日期 2017.02.09
申请号 US201615332472 申请日期 2016.10.24
申请人 Cancer Research Technology Limited 发明人 Jones Keith;Rye Carl;Chessum Nicola;Cheeseman Matthew;Pasqua Adele E.;Pike Kurt G.;Faulder Paul F.
分类号 C07D405/12;C07D471/04;C07D417/12;C07D405/14;C07D407/12;C07D319/18 主分类号 C07D405/12
代理机构 代理人
主权项 1. A compound of formula I shown below: wherein: A1 is selected from N or CR1, A2 is selected from N or CR2, with the proviso that only one of A1 or A2 can be N; R1 and R2 are each independently selected from hydrogen, fluoro, chloro, cyano, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy; R4 is selected from hydrogen, fluoro, chloro, bromo, iodo, CF3, OCF3, cyano, NO2, (1-4C)alkyl, (1-4C)alkoxy, or a group of the formula: W—X—Y—Z wherein W is absent or (1-3C)alkylene; X is —O— or —N(Ra)—, wherein Ra is selected from hydrogen or (1-2C)alkyl; Y is absent or a (1-3C)alkylene; Z is hydrogen, (1-6C)alkyl or (3-6C)cycloalkyl; and wherein any alkylene, alkyl or cycloalkyl group present in a R4 substituent group is optionally further substituted by one or more substituent groups independently selected from halo, hydroxy, NRbRc, (1-2C)alkoxy, (1-2C)haloalkyl or (1-2C)haloalkoxy, and wherein Rb and Rc are each independently selected from hydrogen or (1-3C)alkyl; Q is a group of formula II: wherein A4a and A4b are each independently selected from N or CR9, wherein each R9 present is independently selected from hydrogen, halo, cyano, nitro, hydroxy, NRdRe, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein Rd and Re are each independently selected from hydrogen or (1-3C)alkyl; and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl group present in a R9 substituent group is optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, NRfRg or (1-3C)alkoxy, wherein Rf and Rg are each independently selected from hydrogen or (1-3C)alkyl; A4c is N or CR10; R10 is selected from hydrogen, halo, amino, cyano, nitro, hydroxy or a group W1—X1—Y1—X4—Z1 wherein W1 is absent or a linker group of the formula —[CRhRi]p— in which p is an integer selected from 1, 2, 3 or 4, and Rh and Ri are each independently selected from hydrogen or (1-2C)alkyl; X1 is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(OR)—, —N(Rj)—, —N(Rj)—C(O)—, —N(Rj)—C(O)O—, —C(O)—N(Rj)—, —N(Rj)C(O)N(Rj)—, —S—, —SO—, —SO2—, —S(O)2N(Rj)—, or —N(Rj)SO2—, wherein Rj is selected from hydrogen or methyl; Y1 is absent or a linker group of the formula —[CRkRl]q— in which q is an integer selected from 1, 2, 3 or 4, and Rk and Rl are each independently selected from hydrogen or (1-2C)alkyl; X4 is absent or —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(OR)—, —N(Rj)—, —N(Rj)—C(O)—, —N(Rj)—C(O)O—, —C(O)—N(Rj)—, —N(Rj)C(O)N(Rj)—, —S—, —SO—, —SO2—, —S(O)2N(Rj)—, or —N(Rj)SO2— wherein Rj is selected from hydrogen or methyl; and Z1 is (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl or heterocyclyl; and wherein Z1 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRmRn, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, C(O)NRmRn, NRmC(O)Rn, NRmS(O)2Rn and S(O)2NRmRn; wherein Rm and Rn are each independently selected from hydrogen, (1-4C)alkyl or (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or Rm and Rn can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring; and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z1 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, NRoRp, (1-2C)alkoxy, or (1-2C)alkyl; wherein Ro and Rp are selected from hydrogen or (1-2C)alkyl; with the proviso that R10 is only hydrogen, halo or t-butyl when at least one of A4a and A4b is N or CR9 in which R9 is a substituent as defined above other than hydrogen; or Q is a group of formula III: wherein A5 is selected from N or CR5, where R5 is selected from hydrogen, halo, cyano, nitro, hydroxy, NRqRu, (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl; wherein Rq and Ru are each independently selected from hydrogen or (1-3C)alkyl, and wherein any (1-3C)alkyl, (1-3C)alkoxy, 5 or 6-membered heteroaryl, or 5 or 6 membered heterocyclyl group present in a R5 substituent group is optionally substituted by one or more substituents selected from halo, cyano, nitro, hydroxy, NRvRw, or (1-3C)alkoxy, wherein Rv and Rw are each independently selected from hydrogen or (1-3C)alkyl; Ring A is: a fused phenyl ring; a fused 5 or 6 membered carbocyclic ring; a fused 5 or 6 membered heteroaryl ring comprising one or two heteroatoms independently from N, S or O; or a fused 5, 6 or 7-membered heterocyclic ring comprising one or two heteroatoms independently from N, S or O; A6 is selected from N, O, S, S(O), S(O)2, CR6, C(R6)2, NR60, where R6 is selected from hydrogen, oxo, fluoro, chloro, (1-2C)alkyl, (1-2C)alkoxy, (1-2C)haloalkoxy or (1-2C)haloalkyl and R60 is hydrogen, —O—, (1-6C)alkyl, —C(O)—R61, —C(O)O—R61, or —C(O)N(R62)R61, wherein R61 is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heteroaryl or heterocyclyl and R62 is selected from hydrogen or (1-3C)alkyl; A7 is selected from N, O, CR7, S, S(O), S(O)2, C(R7)2, NR70, where R70 is hydrogen, —O—, (1-6C)alkyl, —C(O)—R71, —C(O)O—R71, or —C(O)N(R72)R71, wherein R71 is selected from hydrogen, (1-6C)alkyl, (3-6C)cycloalkyl, aryl, heteroaryl or heterocyclyl and R72 is selected from hydrogen or (1-3C)alkyl; m is 0, 1 or 2; R7 and R11 are each independently halo, cyano, oxo, or a group W2—X2—Y2—X3—Z2 wherein W2 is absent or a linker group of the formula —[CRxRy]r— in which r is an integer selected from 1, 2, 3 or 4, and Rx and Ry are each independently selected from hydrogen or (1-2C)alkyl; X2 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(OR)—, —N(Rj)—, —N(Rz)—C(O)—, —N(Rz)—C(O)O—, —C(O)—N(Rz)—, —N(Rz)C(O)N(Rz)—, —S—, —SO—, —SO2—, —S(O)2N(Rj)—, or —N(Rz)SO2, wherein Rz is selected from hydrogen or methyl; Y2 is absent or a linker group of the formula —[CRaaRbb]s— in which s is an integer selected from 1, 2, 3 or 4, and Raa and Rbb are each independently selected from hydrogen or (1-2C)alkyl; X3 is absent, —O—, —C(O)—, —C(O)O—, —OC(O)—, —CH(ORcc)—, —N(Rcc)—, —N(Rcc)—C(O)—, —N(Rcc)—C(O)O—, —C(O)—N(Rcc)—, —N(Rcc)C(O)N(Rcc)—, —S—, —SO—, —SO2—, —S(O)2N(Rcc)—, or —N(Rcc)SO2, wherein Rcc is selected from hydrogen or methyl; and Z2 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, aryl, (3-6C)cycloalkyl, (3-6C)cycloalkenyl, heteroaryl, or heterocyclyl, and wherein Z2 is optionally further substituted by one or more substituent groups independently selected from oxo, halo, cyano, nitro, hydroxy, carboxy, NRddRee, (1-4C)alkoxy, (1-4C)alkyl, (3-8C)cycloalkyl, (3-8C)cycloalkyl-(1-3C)alkyl, (1-4C)alkanoyl, (1-4C)alkylsulphonyl, aryl, aryloxy, heterocyclyl, heterocyclyloxy, heterocyclyl-(1-2C)alkyl, heteroaryl, heteroaryloxy, heteroaryl-(1-2C)alkyl, C(O)NRddRee, NRddC(O)Ree, NRddSO2Ree and SO2NRddRee; wherein Rdd and Ree are each independently selected from hydrogen, (1-4C)alkyl, (3-6C)cycloalkyl or (3-6C)cycloalkyl(1-2C)alkyl; or Rdd and Ree can be linked such that, together with the nitrogen atom to which they are attached, they form a 4-6 membered heterocyclic ring; and wherein any alkyl, aryl, heterocyclyl or heteroaryl group present in a substituent group on Z2 is optionally further substituted by halo, cyano, nitro, hydroxy, carboxy, NRffRgg, (1-2C)alkoxy, or (1-2C)alkyl; wherein Rff and Rgg are selected from hydrogen or (1-2C)alkyl; with the proviso that when R7 is hydrogen (i.e. when W2, X2, Y2, and X3 are absent and Z2 is hydrogen) then ring A is not a fused dioxane ring; and when A1 and A2 are both CH and R4 is H, Q is not pyrid-4-yl. or a pharmaceutically acceptable salt or solvate thereof.
地址 London GB